Business Context and Reporting Period
Company: Milestone Scientific Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Milestone develops and markets proprietary, computer-controlled injection technologies for the medical and dental markets. Key products include the STA Single Tooth Anesthesia System, CompuDent, and CompuMed. The company focuses on painless, precise drug delivery using its patented CompuFlo technology.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Total Revenue | $8,549,060 | $6,623,807 |
| Gross Profit | $5,090,781 | $3,942,691 |
| Gross Margin | 60% | 60% |
| Net Loss | $(1,530,085) | $(1,187,454) |
| Operating Cash Flow | $402,951 | $(442,006) |
| Cash and Equivalents (Year End) | $1,029,129 | $743,665 |
| Working Capital | $1,626,073 | $1,532,688 |
| Accumulated Deficit | $(58,763,454) | $(57,233,369) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by approximately 30% ($1.95 million) compared to 2008. This was driven by a 95% increase in domestic instrument sales and a 100% increase in international instrument sales, largely due to the STA System.
- Operating Loss: Despite revenue growth, the net loss increased by 29% to $1.53 million. This was primarily due to a $1.45 million increase in Selling, General, and Administrative (SG&A) expenses, which outpaced the increase in gross profit.
- Cash Flow Turnaround: The company achieved positive operating cash flow of $402,951 in 2009, reversing a negative cash flow of $442,006 in 2008. This was aided by non-cash stock issuances for compensation and vendor services.
- Debt Conversion: In December 2009, the company converted a $1.3 million Line of Credit into 822,785 shares of common stock, eliminating this specific debt obligation.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states that recurring losses raise substantial doubt about the company's ability to continue as a going concern. Management believes current cash reserves are sufficient for the next 12 months, but future capital raises may be necessary.
- Strategic Partnerships: Milestone signed an exclusive distribution agreement with China National Medicines Corporation (Sinopharm), securing a blanket purchase order for 12,000 STA units over 36 months. Additionally, a joint venture was announced with Chinese partners to develop medical applications for CompuFlo technology.
- Market Expansion: The company is refining its international marketing strategy and expanding its distribution network in Europe, Asia, and South America.
- Risks: Key risks include dependence on a limited number of distributors and manufacturers, the need for continued capital to fund operations, and the potential for product liability claims not fully covered by insurance.
Investor Verification Checklist
- Cash Runway: Verify if the $1.03 million cash balance is sufficient to cover the projected operating losses and SG&A increases for the upcoming year without additional financing.
- China Order Execution: Confirm the delivery schedule and revenue recognition timeline for the 12,000-unit purchase order from Sinopharm.
- SG&A Control: Assess whether the significant increase in SG&A expenses (driven by commissions, bonuses, and consulting fees) is sustainable relative to revenue growth.
- Debt Obligations: Review the terms of the remaining $450,000 long-term note payable due in 2012 and the accrued interest payments.
- Stock Dilution: Evaluate the impact of recent and future stock issuances used to pay vendors, employees, and settle debt on existing shareholder equity.